Complete remission observed in 10 weeks with NORA-PLK1 siRNA therapy.
Intranasal NORA therapy led to total tumor regression.
siRNA-based therapy demonstrated neuroprotective effects, reducing disease progression.
Nanora Pharma is at the forefront of pharmaceutical innovation, dedicated to developing advanced treatments that improve lives worldwide. Our passion for science and commitment to health drive us to deliver groundbreaking solutions for today’s medical challenges.
